Haemonetics Corporation (HAE) is a publicly traded Healthcare sector company. As of September 17, 2026, HAE trades at $107.78 with a market cap of $4.83B and a P/E ratio of 50.15. HAE moved +1.44% today. Year to date, HAE is +32.55%; over the trailing twelve months it is +108.23%. Its 52-week range spans $47.32 to $109.57. Analyst consensus is moderatebuy with an average price target of $104.88. Rallies surfaces HAE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for HAE shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $107.78 |
| Market Cap | $4.83B |
| P/E Ratio | 50.15 |
| EPS | $2.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $109.57 |
| 52-Week Low | $47.32 |
| Volume | 1.17K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.35B |
| Net Income | $96.29M |
| Gross Margin | 59.03% |
9 analysts cover HAE: 0 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is moderatebuy. Average price target: $104.88.